L

(redirected from LLY)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

L

Fifth letter of a Nasdaq stock symbol specifying that the issue is a class of stock such as third preferred class of warrants, foreign preferred, sixth class of preferred stock, or preferred when issued stock.

L

On a stock transaction table, a symbol indicating that a security's price is its lowest price in a rolling 52-week period. See also: New low.

L

Used in stock transaction tables in newspapers to indicate that during the day's activity the stock traded at a new 52-week low: L53 1/2 .
References in periodicals archive ?
172(h) if interest expense in the LLY exceeded the prior three-year average solely due to an interest-rate increase.)
The 2000 LLY annual report speaks of its conduct code as a policy "emphasizing proper overall business conduct, possible conflicts of interest, compliance with laws, and confidentiality of proprietary information." [10] When I asked to review this policy to determine the nature of its values orientation, Lilly management said no, because it is "an internal document." [11] It's interesting to note, however, that the LLY values statement says: "Respect for people that includes our concern for the interests of all people worldwide who touch--or are touched by--our company: customers, employees, shareholders, partners, and communities." [12] Thus, the statement doesn't mention the patients, who are the very reason for the company's existence.
Eli Lilly and Company (NYSE: LLY) is a company that is developing a portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organisations.
Mind you, one bidder had obviously managed to keep his sense of humour in tact, paying an astonishing pounds 20,000 for W1 LLY.
Pfizer (PFE) and Eli Lilly (LLY) were initiated with an Overweight at Cantor Fitzgerald.
Eli Lilly and Company (NYSE: LLY), a global pharmaceutical company, announced on 6 July that it has met the United States Food and Drug Administration requirements for pediatric exclusivity for Cymbalta.
And th i s time, i t rea lly is a c as e of A dr ia na i n fur knic ke r s and no c o at!
Tickers featured: AMGN, BEC, BMY, DHR, DOW, GHDX, ILMN, IVGN, LIFE, LLY, LMNX, MDZ, MYGN, QGEN, SGMO, SIAL, TGEN, WAT.
Other top Classic Collection sales were: 1RR (pounds 106,000), 1S (pounds 100,000), G1 LLY (pounds 87,500), P1 LOT (pounds 82,500), 1 DM (pounds 75,000), 1 J (pounds 75,000), ELV 1S (pounds 75,000) and N1 GEL (pounds 75,0 00).
Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).[Reference Link]:[https://www.reuters.com/article/us-health-cancer-fda/fda-wants-to-shorten-new-drug-monopolies-to-cut-costs-idUSKCN1IZ0V2]
Among large pharma companies, Rahimi believes those with the strongest metabolic franchises, large R&D teams, and sales forces focused on endocrinologists, gastroenterologists, and hepatologists likely have eyes on NASH assets, listing Merck (MRK), AstraZeneca (AZN), Eli Lilly (LLY) and Novo Nordisk (NVO) as examples.